The case for & against
Bull & Bear analysis
Bearish
Halyard Health, Inc. (NASDAQ: HYH) was a leading provider of healthcare products, including surgical and infection prevention products, designed to enhance the safety and quality of patient care. The company operated in the medical supplies sector, focusing on infection prevention and control, which placed it within the broader theme of healthcare necessities. However, it has become a delisted company, raising concerns about its operational viability and market position.
Bull says
- ↑Relisting could restore liquidity and share trading.
- ↑Halyard’s established brand in infection control may drive recovery.
- ↑Management aims to stabilize finances and pursue re-listing (Q2 2026).
- ↑Healthcare spending remains robust, supporting potential market reentry.
- ↑52-week low of $9.30 presents potential valuation entry point.
Bear says
- ↓Delisting cuts capital access and impairs trading liquidity.
- ↓P/E of -15.53 signals sustained negative earnings.
- ↓No dividend payments reflect strained cash flow.
- ↓Lack of recent research coverage indicates weak sentiment.
- ↓Strong competition from Cardinal, McKesson, and Medline intensifies risk.
- ↓Operational setbacks limit adoption of supply-chain innovations.